/
HCWB
$3.19-$0.22 (-7.00%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$5.0M
2M shares
52-week range
$1.50 – $44.10
4% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-1216.28
HCW Biologics Inc. Common Stock
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
www.hcwbiologics.com- Employees
- 35
- IPO / List date
- Jul 20, 2021
- HQ
- MIRAMAR, FL
Held by traders on TradeandTell
No one on the platform currently holds HCWB.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in HCWB as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-06-30 | 1-for-6reverse |
| 2025-04-11 | 1-for-40reverse |
Recent trades on TradeandTell
No one on the platform has traded HCWB yet.
